Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDMD NASDAQ:FEMY NASDAQ:OSRH NASDAQ:POAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDMDBaird Medical Investment$3.71-1.3%$4.94$1.05▼$12.50$24.41M-0.94354,560 shs12,581 shsFEMYFemasys$0.91-1.3%$0.98$0.69▼$1.80$29.60M-2.56263,364 shs29,341 shsOSRHOSR$1.25-6.0%$1.33$1.02▼$13.40$24.10M1.562.33 million shs1.49 million shsPOAIPredictive Oncology$0.78-2.9%$0.96$0.55▼$3.06$6.94M1.171.93 million shs38,629 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDMDBaird Medical Investment-7.39%-2.59%-16.26%-29.59%+375,999,900.00%FEMYFemasys-1.00%-1.86%+15.00%-22.03%-19.30%OSRHOSR0.00%-11.92%-2.21%-13.07%+132,999,900.00%POAIPredictive Oncology-5.88%-3.85%-14.77%-20.00%-23.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDMDBaird Medical InvestmentN/AN/AN/AN/AN/AN/AN/AN/AFEMYFemasys3.7062 of 5 stars3.55.00.00.03.32.50.6OSRHOSRN/AN/AN/AN/AN/AN/AN/AN/APOAIPredictive Oncology2.2926 of 5 stars3.05.00.00.02.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDMDBaird Medical Investment 0.00N/AN/AN/AFEMYFemasys 3.00Buy$8.67854.48% UpsideOSRHOSR 0.00N/AN/AN/APOAIPredictive Oncology 2.00Hold$3.00286.10% UpsideCurrent Analyst Ratings BreakdownLatest POAI, OSRH, BDMD, and FEMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDMDBaird Medical InvestmentN/AN/AN/AN/AN/AN/AFEMYFemasys$1.63M18.12N/AN/A$0.10 per share9.08OSRHOSRN/AN/AN/AN/A($3.87) per shareN/APOAIPredictive Oncology$1.73M4.01N/AN/A($0.03) per share-25.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDMDBaird Medical InvestmentN/AN/A0.00∞N/AN/AN/AN/AN/AFEMYFemasys-$18.82M-$0.91N/AN/AN/A-1,242.06%-392.45%-137.15%8/14/2025 (Estimated)OSRHOSR-$2.41MN/A0.00∞N/AN/A-36.89%-19.14%N/APOAIPredictive Oncology-$12.66M-$3.05N/AN/AN/A-629.68%-671.29%-132.49%8/12/2025 (Estimated)Latest POAI, OSRH, BDMD, and FEMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025OSRHOSRN/A-$1.04N/A-$1.04N/A$0.76 million5/14/2025Q1 2025POAIPredictive Oncology-$0.09-$0.32-$0.23-$0.34$1.50 million$0.11 million5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDMDBaird Medical InvestmentN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDMDBaird Medical InvestmentN/AN/AN/AFEMYFemasys0.020.930.54OSRHOSRN/A0.250.20POAIPredictive OncologyN/A0.760.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDMDBaird Medical Investment19.78%FEMYFemasys65.27%OSRHOSR55.30%POAIPredictive Oncology9.04%Insider OwnershipCompanyInsider OwnershipBDMDBaird Medical Investment78.90%FEMYFemasys11.54%OSRHOSR33.67%POAIPredictive Oncology3.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDMDBaird Medical InvestmentN/A6.58 million1.39 millionN/AFEMYFemasys3032.53 million22.60 millionNot OptionableOSRHOSRN/A19.28 million12.79 millionN/APOAIPredictive Oncology308.93 million8.63 millionNot OptionablePOAI, OSRH, BDMD, and FEMY HeadlinesRecent News About These CompaniesPredictive Oncology Shares Slip After Signing $10M Equity Purchase AgreementJuly 8 at 8:00 PM | msn.comPredictive Oncology Inc. Enters Standby Equity Purchase Agreement with Yorkville Advisors for Up to $10 Million in FundingJuly 8 at 9:44 AM | quiverquant.comQPredictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and RepurposingJuly 8 at 9:00 AM | globenewswire.comPredictive Oncology Inc. (POAI) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.com6 Ways Predictive Maintenance Impacts Concrete Truck OpsJuly 2, 2025 | forconstructionpros.comFPredictive Discovery’s DFS for Bankan delivers good returnsJuly 2, 2025 | miningreview.comMAgenus, Noetik Partner to Discover Predictive Immuno-Oncology Biomarkers Using AI Foundation ModelJune 17, 2025 | precisionmedicineonline.comPPredictive Oncology Inc. Develops Exclusive 3D Organoid Models for Labcorp to Enhance Drug Discovery and Safety EvaluationJune 12, 2025 | quiverquant.comQPredictive Oncology Develops Functional 3D Organoid Models Exclusively for LabcorpJune 12, 2025 | globenewswire.comPredictive Oncology Inc.: Court Denies Renovaro Motion for an Expedited Trial in JulyMay 27, 2025 | finanznachrichten.deCourt Denies Renovaro Motion for an Expedited Trial in JulyMay 27, 2025 | globenewswire.comPredictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans BullishMay 23, 2025 | msn.comPredictive Oncology Inc. Advances AI-Driven Drug Discovery with Extensive Biobank of Tumor SamplesMay 22, 2025 | quiverquant.comQAI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe AcquisitionMay 22, 2025 | globenewswire.comPredictive Oncology Expands AI-Driven Platform to Include Biomarker Discovery and Drug Repurposing for Precision OncologyMay 22, 2025 | nasdaq.comPredictive Oncology reports loss, but has "meaningfully expanded the potential" of its AI platformMay 20, 2025 | bizjournals.comPredictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"May 20, 2025 | globenewswire.comPredictive Oncology Inc. Reports Q1 2025 EarningsMay 16, 2025 | tipranks.comPredictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | globenewswire.comPredictive Oncology develops new approach to identifying viable abandoned drugsApril 16, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePOAI, OSRH, BDMD, and FEMY Company DescriptionsBaird Medical Investment NASDAQ:BDMD$3.71 -0.05 (-1.33%) As of 10:33 AM EasternBaird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.Femasys NASDAQ:FEMY$0.91 -0.01 (-1.30%) As of 10:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.OSR NASDAQ:OSRH$1.25 -0.08 (-6.02%) As of 10:33 AM EasternOSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.Predictive Oncology NASDAQ:POAI$0.78 -0.02 (-2.88%) As of 10:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
